MOG autologous T-lymphocyte cell therapy (ImCyse)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMOG autologous T-lymphocyte cell therapy (ImCyse)
Drug Alias NameMOG cytolytic CD4+ T-cell therapyMOG peptide gene therapyMOG gene therapyMyelin oligodendrocyte glycoprotein transduced T cell therapy
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMyelin-oligodendrocyte glycoprotein expression stimulants
TargetsMyelin-oligodendrocyte glycoprotein
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImcyse Sa
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcImcyse Sa
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A